 The FDA has accused CytoDyn Inc OTC: CYDY of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is effective. In March, the Phase 3 trial of CytoDyns leronlimab failed on the primary goal of reducing symptoms and all secondary goals, including one that questioned whether the therapy could reduce mortality. 